Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAOR.L Regulatory News (AOR)

  • There is currently no data for AOR

Milestone Payment

18 Mar 2008 07:00

Aortech International PLC18 March 2008 18 March 2008 AorTech International plc ("AorTech" or the "Company") Milestone payment AorTech International plc (AIM: AOR), the biomaterials and medical devicedevelopment company, announces that it has received a material milestone paymentfrom St. Jude Medical (NYSE:STJ). This payment relates to the licensing andsupply agreement announced on 20 July 2006. The milestone payment extends the exclusive use of Elast-Eon 2 in the field ofcardiac pacing, ICD (implantable cardiac defibrillator) and cardiac monitoringleads into perpetuity. One further optional milestone payment, contingent on theissue of new AorTech polymer intellectual property, would occur sometime in Q42009. Frank Maguire, AorTech CEO said, "The partnership with St. Jude Medical has beena productive one and we look to the growth of this relationship in the future.This payment forms part of management expectations for revenue in the currentyear." -Ends- For further information please contact: AorTech International plcFrank Maguire, Chief Executive Tel: + 1 801 201 4336 Evolution SecuritiesBobbie Hilliam Tel: +44 20 7071 4300Chris Clarke Hogarth Partnership Limited Tel: +44 20 7357 9477Melanie Toyne-Sewell / Sarah Richardson Notes to editors: About AorTech International plc Listed on AIM in London, AorTech International plc wholly owns AorTechBiomaterials based in Melbourne, Australia. AorTech Biomaterials was formed inJuly 1997 to commercialise a range of medical grade polyurethanes for medicalimplants developed by the Commonwealth Scientific and Industrial ResearchOrganisation (CSIRO). AorTech's Elast-EonTM technology is the product of a decade of fundamentalresearch into biologically stable materials. Elast-EonTM materials are patented,high silicone content, polyurethane copolymers which exhibit unparalleledbiological and mechanical performance. AorTech is firmly focused on the development and refinement of this material forthe medical community, with the aim of providing a wide range of highperformance Elast-EonTM materials in a variety of application specificformulations and densities, for use in medical devices. Visit AorTech's website at: www.aortech.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Sep 20067:03 amRNSAGM Statement
19th Sep 20064:47 pmRNSHolding(s) in Company
15th Sep 20065:09 pmRNSDirector/PDMR Shareholding
13th Sep 20061:32 pmRNSHolding(s) in Company
13th Sep 20061:31 pmRNSHolding(s) in Company
6th Sep 200612:13 pmRNSAnnual Report and Accounts
5th Sep 20067:03 amRNSDirector/PDMR Shareholding
5th Sep 20067:02 amRNSHolding(s) in Company
31st Aug 20067:01 amRNSFinal Results
15th Aug 20067:00 amRNSMedical Advisory Board
7th Aug 20067:02 amRNSFirst human use of ElastEon
1st Aug 20062:20 pmRNSHolding(s) in Company
19th Jul 20067:01 amRNSHolding(s) in Company
30th Jun 200612:20 pmRNSDirector/PDMR Shareholding
23rd Jun 200611:01 amRNSHolding(s) in Company
28th Apr 20063:38 pmRNSConference Presentation
13th Apr 200611:36 amRNSChange of Adviser
6th Apr 20064:06 pmRNSNotification of Interests
20th Mar 20067:01 amRNSSupply and License Agreement
24th Jan 20068:54 amRNSAward of Govt Grant Funding
9th Dec 20057:01 amRNSInterim Results
7th Dec 20057:01 amRNSUpdate of Postal Poll
25th Nov 20057:00 amRNSFDA Approval
17th Nov 20057:01 amRNSAGM Update
15th Nov 20052:25 pmRNSDirectorate Change
27th Oct 20051:06 pmRNSAGM Statement
23rd Sep 20057:01 amRNSFinal Results
1st Aug 20057:01 amRNSSpinal Disc Licence
13th May 20057:00 amRNSBoard Changes
29th Apr 20057:00 amRNSBreast Implants Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.